Testicular germ cell tumours (GCTs) represent the most frequent malignancy among men aged 20--35 years ([@bib7]). Today, GCT is a paradigm of a curable cancer. Clinical management is greatly based on serum biomarker monitoring ([@bib1]). Markers currently used involve *α*-fetoprotein (AFP), *β*-human chorionic gonadotropin (bHCG), and lactate dehydrogenase (LDH) ([@bib3]), but only 60% of all GCT patients have elevations of these markers and, particularly, LDH shows a quite low specificity ([@bib3]).

Thus, there is still an ongoing need for new biomarkers in the field. MicroRNAs (miRNAs) are small RNA molecules involved in several biological processes that cover embryogenic development, cell differentiation, apoptosis, and tumorigenesis ([@bib4]; [@bib11]; [@bib8]; [@bib12]). They have gained a lot of interest because of their potential use as biomarkers in various cancer types because some of these molecules are abundantly expressed in cancer tissues ([@bib9]) and most of them reveal high stability in body fluids ([@bib27]).

The miR-371-3 cluster encodes of seven mature miRNAs and apparently belongs to a larger imprinted region of the long arm of chromosome 19. It can be speculated that akin to C19MC, that is, a juxta-posed cluster ([@bib25]; [@bib32]) miR-371-3 underlies epigenetic silencing in adult somatic cells.

In human testicular GCTs, miR-372 and miR-373-3p have an oncogenic potential allowing the cells to display tumorigenic growth in the presence of wild-type p53 ([@bib31]; [@bib14]).

Recently, [@bib26] have profiled and analysed the miRNA expression in malignant GCTs. As a rule, the clusters miR-371-3 and miR-302 were found to be overexpressed in this malignancy. Interestingly, the corresponding miRNAs can also be detected in serum: high expression of miRNAs of these clusters was demonstrated in the serum of a 4-year-old boy with a yolk sac tumour. After chemotherapy the level strongly declined ([@bib5]). In a recent report on eleven GCT- cases the average expression of the miR-371-3 declined after surgery ([@bib5]). These reports indicate that assessing miR-371-3 in serum might be clinically valuable.

We looked to the levels of miR-371-3 in serum and to the expression of these miRNAs in tumour tissue in a consecutive series of GCT patients. Our aim was to evaluate the potential use of miRNAs 371-3 as new biomarkers in this disease.

Materials and methods
=====================

Patients, blood, and tumour samples
-----------------------------------

From 1 June 2011 to 21 May 2012, a total of 24 patients with histologically proven GCT (13 pure seminoma, 11 nonseminoma) were enrolled in this prospective study. Median age was 37 (18--60) years. Cubital vein blood samples were obtained during routine blood examinations usually 3 days before orchiectomy and 5--6 days postoperatively. Eleven of these patients have been briefly documented previously ([@bib5]). In six patients, testicular vein blood (TVB) samples were analysed too.

All patients had given informed consent. The study had been approved by the local ethics committee. Twenty patients had clinical stage 1 disease ([Table 1](#tbl1){ref-type="table"}). Serum aliquots were frozen within 2 h of receipt and stored at −80°C before further processing. Seventeen male patients, aged 23--51 years (median 37), with non-malignant scrotal diseases served as controls.

To study miRNAs serum levels during the course of chemotherapy in metastasised disease, four patients with nonseminomatous GCT with stages IIa--III (Lugano classification) were examined (cases 21--24, [Table 1](#tbl1){ref-type="table"}). In these cases, blood samples were drawn before the start of treatment and repeatedly during the three or four chemotherapy cycles and finally after completion of therapy. Chemotherapy consisted of cisplatin, etoposide, and bleomycin according to current guidelines ([@bib16]).

Formalin-fixed and paraffin-embedded (FFPE) tumour tissue samples of 15 patients were analysed additionally.

RNA Isolation
-------------

For RNA isolation from serum samples 200 *μ*l frozen serum was thawed on ice, total RNA extracted using the miRNeasy Mini Kit (Qiagen, Hilden, Germany) and RNA was quantified by spectrophotometry (Eppendorf, Hamburg, Germany).

Total RNA from six 5-*μ*m sections of each FFPE tumour specimen was prepared using the innuPREP Micro RNA Kit (Analytik Jena AG, Jena, Germany) according to the manufacturer\'s instructions with a few modifications. Lysis of the paraffin sections preceding RNA isolation was conducted using TLS-lysis solution and Proteinase K from the innuPREP DNA Micro Kit (Analytik Jena AG) without prior deparaffinisation. Sections were incubated for 1 h at 60°C and 15 min at 80°C ([@bib13]).

cDNA synthesis
--------------

For serum samples reverse transcription (RT) was carried out using the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems, Darmstadt, Germany). Fifty-five nanograms of total RNA from each sample was used.

Reverse transcription primers represented an equal mixture of three miRNA (miR-371a-3p, miR-372, miR-373-3p)-specific stem-loop-primers from the relevant miRNA assays (Applied Biosystems). The reactions with a final volume of 15 *μ*l were incubated in the GeneAmp PCR-System 2700 (Applied Biosystems) at 16°C for 30 min, 42°C for 30 min, and 85°C for 5 min, respectively.

For the 18S rRNA assay, RNA of each sample was reverse transcribed with 200 U *μ*l^−1^ of M-MLV reverse transcriptase (Invitrogen, Karlsruhe, Germany), RNase-Out, 150 ng random hexamers, 2 *μ*l 0.1 M DTT, 4 *μ*l 5 × first strand buffer and 100 mℳ dNTPs according to the manufacturer\'s instructions. RNA was initially denatured at 65°C for 5 min and subsequently kept on ice for 1 min. Reverse transcription was performed at 37°C for 50 min followed by inactivation of the reverse transcriptase at 70°C for 15 min.

On FFPE tumour specimens RT was carried out for miR-371a-3p and RNU6B as endogenous control using the TaqMan MicroRNA Reverse Transcription Kit and stem-loop-primers from the relevant TaqMan microRNA assays (Applied Biosystems) with 200 ng of RNA per sample as described earlier ([@bib28]).

Preamplification of RT products
-------------------------------

Preamplification has been carried out by [@bib23] and we have thus also performed preamplification for serum samples. One microgram of each miRNA assay was diluted in 12 *μ*l nuclease-free water. The PCR with a final volume of 50 *μ*l (12.5 *μ*l of this solution, 12.5 *μ*l of RT product, 25 *μ*l TaqMan Universal PCR Master Mix (Applied Biosystems)) was performed at 95°C for 10 min, followed by 14 cycles of 95°C for 15 s and 60°C for 4 min using the GeneAmp PCR-System 2700 (Applied Biosystems). Endogenous controls were processed in identical manner. The preamplification product was diluted 1 : 5 in nuclease-free water.

Quantitative real-time PCR
--------------------------

For the quantitative real-time PCR, 9 *μ*l of the preamplification product was added to 10 *μ*l TaqMan Universal PCR Master Mix and 1 *μ*l of 20 × TaqMan microRNA assay using the Applied Biosystems 7300 real-time PCR System (Applied Biosystems). The relative quantification was performed with 18S rRNA as endogenous control ([@bib17]; [@bib15]). For each sample the reactions were performed in triplicate. A negative control of amplification was performed for each sample without reverse transcriptase. Non-template negative controls for each miRNA and 18S rRNA were included in every plate. PCR conditions were 10 min at 95°C, followed by 40 cycles at 95°C for 15 s, and 60°C for 1 min. Data were analysed using the 7300 system software (Applied Biosystems). Cycle threshold (Ct) values were normalised to the internal control, 18S rRNA ([@bib19]; [@bib2]).

The quantitative real-time PCR for FFPE tumour tissue samples was performed without prior preamplification using the TaqMan Universal PCR Master Mix and TaqMan microRNA assay as described earlier ([@bib28]).

Measurements of serum tumour markers
------------------------------------

The serum tumour markers bHCG, AFP and LDH were measured according to laboratory medicine practice guidelines ([@bib29]).

Statistical analysis
--------------------

Descriptive statistical analysis was performed using Excel software (Microsoft Corp., Redmond, WA, USA). Statistical comparisons of preoperative with postoperative serum levels were performed by using the two-sided Mann--Whitney *U*-test. We also performed statistical comparisons of serum levels of GCT patients with controls. A *P-*value of less than 0.05 was considered significant.

Results
=======

miRNAs serum levels in comparison with controls
-----------------------------------------------

Preoperative serum levels of all three miRNAs were much higher in GCT patients than levels found in controls ([Figure 1](#fig1){ref-type="fig"}). These differences were statistically significant with *P*-values of *P*\<0.0001, *P*\<0.01, and *P*\<0.001 regarding miR-371a-3p, miR-372, and miR-373-3p, respectively. By looking closer, it became clear that individual values varied considerably but values of patients exceeded the mean value of controls in 17, 15, and 16 cases, respectively, for miR-371a-3p, miR-372, and miR-373-3p. Likewise, 16, 8, and 7 cases had serum levels higher than the highest value determined among controls for miR-371a-3p, miR-372, and miR-373-3p. Interestingly, the two teratomas included in this study had serum levels in the range of controls for all three miRNAs whereas 11out of 13 seminomas showed serum levels clearly exceeding those of controls. With regard to classical biomarkers, AFP was increased in four patients and bHCG in two ([Table 1](#tbl1){ref-type="table"}).

miRNA levels after surgery
--------------------------

In the stage 1 cases, serum levels of each of the three miRNAs decreased significantly after orchiectomy ([Figure 1](#fig1){ref-type="fig"}) with a 336.7-fold (*P*\<0.0001), 7.4-fold (*P*\<0.001), and 7.7-fold (*P*\<0.0001) level reduction for miR-371a-3p, miR-372, and miR-373-3p, respectively. Nevertheless, changes of individual serum levels varied considerably across the sample. The greatest change subsequent to surgery was noted with miR-371a-3p. It is Noteworthy that all of the patients had a decline of this miRNA ([Figure 2A](#fig2){ref-type="fig"}). With regard to miR-372 and miR-373-3p, two patients did not show postoperative decline ([Figure 2B and C](#fig2){ref-type="fig"}).

miRNA serum levels in TVB
-------------------------

If the elevated miRNA levels as determined in the GCT patients result from their secretion by the tumour one would expect their local concentration in serum of TVB to be higher than in serum of the cubital vein blood. Serum levels of all three miRNAs in TVB clearly exceeded the levels in peripheral blood in all of the six patients evaluated ([Figure 3A--C](#fig3){ref-type="fig"}). This result suggests that the level of miRNA expression decreases along a gradient surrounding the tumour.

miRNA serum levels during chemotherapy
--------------------------------------

In the four cases with advanced disease, levels decreased to the normal range after the completion of treatment. Two of the cases had the second serum test taken after surgery and the first cycle of chemotherapy ([Figure 4A and B](#fig4){ref-type="fig"}), while the other two cases had the second analysis done right after surgery but before initiation of chemotherapy ([Figure 4C and D](#fig4){ref-type="fig"}). In these latter cases only a slight decrease of the postoperative levels of miRNAs miR-371a-3p, miR-372, and miR-373-3p was noted ([Figure 4C and D](#fig4){ref-type="fig"}). However, a marked reduction occurred after the first cycle of chemotherapy, leading to miRNA levels within the range of controls after completion of therapy akin to the former two cases. Obviously, miRNAs circulating in the serum are not only derived from the primary tumour but also from metastatic tissue.

Matching of miRNA expression in tumour tissue with miRNA serum levels
---------------------------------------------------------------------

We restricted this analysis to miR-371a-3p because this miRNA had shown the greatest pre-/postoperative changes in serum. The expression of miR-371a-3p varied considerably among the 15 tumour samples ([Figure 5A](#fig5){ref-type="fig"}). In matching the miRNA expression level of the tumour tissue with the corresponding serum levels, no obvious correlation was found ([Figure 5B](#fig5){ref-type="fig"}). Also, tumour volume was not associated with serum levels of miRNA-371a-3p (data not shown). Thus, the extent of miRNA serum levels does not mirror the expression of the corresponding miRNAs in tumour tissue. So, other unknown factors seem to contribute largely to the release of miRNAs into the patient\'s blood.

Discussion
==========

The central result of this study is the documentation of increased serum levels of miRNAs miR-371-3 in patients with testicular GCTs followed by their significant decline after the completion of treatment. Of the three miRNAs quantified, miR-371a-3p appears to be the most promising marker because it revealed a considerably high expression, particularly in seminomas and also the most intense postoperative decrease. Therapy-related changes of serum levels of miRNA-371-3 were first demonstrated by [@bib23] in a patient with paediatric GCT. The present results are fully in line with that initial report as all of the stage 1 patients uniformly demonstrated a decline of serum miRNA levels into the range of controls thus being compatible with the presumably tumour-free status after orchiectomy. Moreover, four patients with disseminated disease showed gradual decline of serum levels entering the normal range after completion of treatment. Obviously, the dropping of miRNA serum levels mirrors the decreasing amount of vital tumour tissue during the course of chemotherapy.

The post-surgery measurements had usually been performed within 1 week after orchiectomy. The return of elevated miRNA levels into normal range within that time-span suggests a rapid clearance rate of only few days or even less. This assumption is corroborated by nearly identical findings in most of the patients examined. In fact, the cancer-related elevation of miR-371a-3p serum levels and their rapid clearance subsequent to cancer treatment constitute attributes of a useful biomarker of testicular GCTs. Generally, miRNAs released into body fluids seem to have a great potential as biomarkers of various diseases ([@bib21]; [@bib27]; [@bib34]; [@bib9]; [@bib18]; [@bib22]). In particular, miRNA-141 and miRNA-375 have been suggested to represent robust serum biomarkers of prostatic cancer. With regard to GCTs, members of the miRNA-302 and miRNA-371-3 clusters have been found to be overexpressed in tumour cells ([@bib20]; [@bib24]; [@bib26]; [@bib18]). The tumour tissue examinations reported here are in accordance with that experience. miRNA-371-3 serum levels can be measured by widely standardised quantitative real-time PCR techniques. Yet, elevated miRNA serum levels have been reported in no more than a dozen GCT patients so far ([@bib23]; [@bib5]). Currently the finding of divergent expression of miRNA levels in tumour tissue and in corresponding serum remains unresolved. However, much higher miRNA levels in TVB serum than in peripheral blood serum may point to the tumour-bearing testis as the source of blood-level elevation of miR-371a-3p. As pointed out by [@bib23] these features make this molecule a promising biomarker for testicular GCTs.

Nonetheless, still many issues need to be resolved. So far, it is unknown as to how specific the miRNA-371-3 cluster is in regard to GCTs. Actually, these miRNAs have been found overexpressed in thyroid neoplasms, too ([@bib28]), as a result of chromosomal rearrangements targeting the cluster ([@bib6]). Thus, the presence of thyroid adenomas might instigate false-positive results and should be subject of further studies. Nevertheless, although limited by the still low number of patients evaluated so far, miR-371a-3p apparently involves high sensitivity matching or even exceeding that of the existing markers. Clearly, the three biomarkers currently in use (AFP, bHCG, and LDH) are extremely valuable tools with respect to clinical management of GCT patients ([@bib16]). But, shortcomings result from insufficient specificity with a lack of expression of these biomarkers in major sub-populations of GCT patients. Accordingly, only 20% of seminoma patients have increased bHCG whereas AFP is never elevated in seminomas ([@bib33]). In only 60--70% of the patients with nonseminomatous GCTs, one of the classic markers, AFP and bHCG, is elevated ([@bib10]; [@bib30]; [@bib3]). It is noteworthy that only one-quarter of our stage 1 patients (*n*=5) had elevations of the classical markers whereas all three miRNAs were elevated in three quarters or more of the patients (15--17 of 20 cases).

In GCT new biomarkers are particularly appreciated as the traditional imaging techniques used for clinical follow-up are increasingly disdained because of the untoward radiation exposure to young individuals. In addition, new markers would be useful because international patterns of care are shifting by favouring expectant strategies with no immediate treatment after surgery ([@bib1]).

Perspectives
------------

Ever since the introduction of bHCG and AFP into clinical use, a large variety of new biomarkers have been suggested to aid monitoring GCT patients. But, none has made its way into clinical practice. The use of miRNA serum levels may open up a new dimension of biomarkers combining the prospects of possibly high specificity and sensitivity in GCT patients. The data reported herein are promising, but clearly, much is yet to be done to refine the method, technically, and to define, clinically, what kind of patients might best benefit from it.
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The University of Bremen has filed a patent application for the use of miR-371-3 for the diagnosis of tumours with 19q13 rearrangements.

![Results of the relative miRNA quantifications in GCTs and controls. The mean values of the three miRNAs, miR-371a-3p, miR-372, and miR-373-3p, in serum of 20 patients with GCTs, pre- and postoperatively. C: mean value of 17 controls; \*\*highly significant, \*\*\*extremely significant. The y axis is plotted on a log~10~ scale. 18S rRNA was used as endogenous control and post-surgery sample of case number 1 served as calibrator.](bjc2012469f1){#fig1}

![(**A**--**C**) Results of miR-371-3 quantification in 20 individual GCT patients with clinical stage 1. Comparison of preoperative () and postoperative () miRNA serum levels. (**A**) miR-371a-3p. (**B**) miR-372. (**C**) miR-373-3p. The y axis is plotted on a log~10~ scale. Case numbers are identical with those in [Table 1](#tbl1){ref-type="table"}.](bjc2012469f2){#fig2}

![Levels of miRNAs 371-3 in TVB in comparison with levels in preoperative cubital vein blood (CVB) in six GCT patients. The y axis is plotted on a log~10~ scale.](bjc2012469f3){#fig3}

![(**A--D**) Results of miR-371-3 quantification in four GCT patients with nonseminoma clinical stage 3 (**A**, **B**), stage 2a (**C**), and stage 2b (**D**), respectively. Serial measurements of miR-371-3 expression in serum from time of diagnosis to completion of chemotherapy. : miR-371a-3p. : miR-372. : miR-373-3p. The y axis is plotted on a log~10~ scale. Black arrow indicates the timing of surgery of the primary tumour and grey arrows indicate the timing of chemotherapy cycles.](bjc2012469f4){#fig4}

![Results of the relative level of miR-371a-3p in tumour tissue and in serum of 15 GCT patients, preoperatively. (**A**) Expression of miRNA-371a-3p in tumour samples. (**B**) Diagram showing the expression of miR-371a-3p in tumour specimens and its presence in serum, preoperatively, revealing no obvious correlation.](bjc2012469f5){#fig5}

###### Clinical features of 20 patients with clinical stage 1 disease (cases 1--20) and of four patients with clinical stage 2a (case 23), 2b (case 24), 3 (case 21 and 22) (Lugano classification)

                                **bHCG (IU l^−1^)**   **AFP (ng ml^−1^)**    **LDH (U l^−1^)**                 
  ---- ---- ---- ----- -------- --------------------- --------------------- ------------------- ------- ------ -----
  1     NS  21   2.6   9.20     3.5                   \<1.20                        NA          0.91     n.a.  172
  2     S   55   1.5   1.77     \<1.20                \<1.20                       4.69         4.49     160   160
  3     S   39   1.5   1.77     \<1.20                \<1.20                       1.82         1.66     145   159
  4     NS  28   2.5   8.18     1495.9                62.3                        113.92        37.92    173   169
  5     S   41   5.5   87.11    \<1.20                \<1.20                       4.48         4.39     187   NA
  6     NS  18   2.0   4.19     \<1.20                \<1.20                       2.26         1.86     240   180
  7     NS  23   1.8   3.05     \<1.20                \<1.20                       1.31         1.31     166   195
  8     S   38   2.8   11.49    \<1.20                \<1.20                       3.26         2.39      NA   154
  9     NS  39   3.5   22.45    \<5                   \<1.20                      183.35        8.15     245   192
  10    S   45   1.1   0.70     \<1.20                \<1.20                       4.25         4.26     186   208
  11    S   50   1.5   1.77     \<1.20                \<1.20                       0.41         0.51     185   222
  12    S   60   1.6   2.15     \<1.20                \<1.20                       19.09        19.85    291   248
  13    S   39   6.5   143.79   2.6                   \<1.20                       2.56         1.72     224   180
  14    NS  35   3.5   22.45    \<1.20                \<1.20                      102.73        71.91    183   171
  15    S   26   3.3   18.82    44                    1.4                          1.26         0.79     186   216
  16    S   46   2.4   7.24     \<1.20                \<1.20                       4.85         4.05     192   291
  17    NS  28   0.9   0.38     \<1.20                \<1.20                        1.3         1.1      153   140
  18    S   48   1.5   1.77     \<1.20                \<1.20                       1.62         1.79     170   220
  19    S   41   2.5   8.18     \<1.20                \<1.20                       2.07         4.98     225   185
  20    S   41   5.0   65.45    \<1.20                1.20                         5.07         3.80     331   235
  21    NS  23   6.0   113.10   \>200 000             4829.7                       7.31         3.01     3149  376
  22    NS  46   6.5   143.79   18.09                 \<1.20                      737.60        78.66    2098  386
  23    NS  27   2.0   4.19     67.10                 73.80                        2.18         2.32     202   202
  24    NS  29   1.9   3.59     2.20                  2.20                         1.77         1.56     220   181

Abbreviations: AFP=*α*-fetoprotein; NA=not available; NS=non-seminoma; LDH=lactate dehydrogenase; S=seminoma.

Histology of tumours, patient age, and classical serum tumour markers (normal ranges bHCG: 0--6 IU l^−1^; AFP: 0--10.5 ng ml^−1^; LDH: 120--240 U l^−1^).

Cases 21 and 22: post-surgery measurements refer to analysis after first chemotherapy cycle. The median follow-up period is 6 months. None of the patients has relapsed so far.
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